Orion OYJ (OTCMKTS:ORINY) Shares Gap Down - Here's Why

Key Points

• Orion OYJ's share price dropped significantly, opening at $36.40 after closing at $41.48, marking a 12.2% decline.
• The company reported a net margin of 22.61% and a return on equity of 38.68% for its last quarter, which saw a revenue of $472.57 million.
• Orion OYJ develops and markets various pharmaceuticals, including treatments for prostate cancer and Parkinson's disease, and is active in multiple international markets.

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY - Get Free Report)'s share price gapped down before the market opened on Thursday . The stock had previously closed at $41.48, but opened at $36.40. Orion OYJ shares last traded at $36.40, with a volume of 127 shares.

Orion OYJ Price Performance

The company has a market cap of $10.85 billion, a P/E ratio of 26.14 and a beta of 0.10. The company has a fifty day moving average price of $38.14 and a two-hundred day moving average price of $32.35. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.05 and a current ratio of 1.86.

Orion OYJ (OTCMKTS:ORINY - Get Free Report) last released its quarterly earnings results on Friday, July 18th. The company reported $0.33 earnings per share for the quarter. The company had revenue of $472.57 million during the quarter. Orion OYJ had a net margin of 22.61% and a return on equity of 38.68%. On average, sell-side analysts anticipate that Orion OYJ Unsponsored ADR will post 1.18 earnings per share for the current fiscal year.

About Orion OYJ

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.